NCT00509821已完成2 期
Enzastaurin Before and Concomitant With Radiation Therapy, Followed by Enzastaurin Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma Without Methylation of the Promoter Gene of MGMT Enzyme - a Phase II Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Percentage of Participants With Progression Free Survival at 6 Months (PFS-6)
研究概览
简要总结
The purpose of the protocol was to induce a novel radiochemotherapy with enzastaurin as first-line treatment regimen in glioblastoma: Participants with active, unmethylated MGMT promoter were treated with enzastaurin before, concomitant, and after radiotherapy to determine safety and PFS at 6 months (PFS-6) in phase II.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Present with newly diagnosed histologically proven supratentorial GBM.
- •Demonstration of an unmethylated MGMT-promotor
- •Participants must sign an informed consent document. Participants must be at least 18 years of age.
- •Estimated life expectancy of at least 12 weeks
- •Tumor tissue specimens (paraffin-embedded and/or frozen) from the GBM surgery or biopsy must be available for central pathology review and exploratory analysis of PKC-beta targets (for example, GSK3beta).
- •Disease evaluated by Gd-MRI (magnetic resonance imaging) within 72 hours postoperatively
- •Interval of greater than or equal to 2 and less than or equal to 4 weeks since surgery or biopsy
- •ECOG Performance Status of less than or equal to 2
- •Adequate organ function including the following:
- •adequate bone marrow reserve: white blood cell (WBC) count greater than or equal to 3.0 X 109/L, absolute neutrophil count (ANC) greater than or equal to 1.5 X 109/L, platelet count greater than or equal to 75.0 X 109/L, and hemoglobin greater than or equal to 10.0 g/dL (greater than or equal to 6.2 mmol/L).
- •Hepatic: bilirubin less than or equal to 1.5 times the upper limit of normal (X ULN), alkaline phosphatase (ALP), aspartate transaminase (AST), and alanine transaminase (ALT) less than or equal to 2.5 X ULN, or less than or equal to 5 X ULN with liver metastases
- •Renal: serum creatinine less than or equal to 1.5 X ULN
- •Blood clotting: prothrombin time (PT) and partial thromboplastin time (PTT) within normal limits
- •Participants must discontinue use of enzyme-inducing antiepileptic drugs (EIAEDs) greater than or equal to 14 days prior to study enrollment. The investigator may prescribe non-EIAEDs. Participants who must begin EIAED therapy while on study will be allowed to remain on study.
- •Clinically normal cardiac function without history of ischemic heart disease in the past 6 months and normal 12-lead electrocardiogram (ECG); no history of stroke
排除标准
- •Have a prior malignancy (other than glioblastoma, or adequately treated carcinoma in situ of the cervix, or nonmelanoma skin cancer), unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence
- •Unable to undergo Gd MRI
- •Prior chemotherapy within the last 5 years
- •Prior chemotherapy for a brain tumor
- •Prior radiotherapy of the head
- •Are unable to discontinue use of carbamazepine, phenobarbital, and phenytoin
- •History of coagulation disorder associated with bleeding, or recurrent thrombotic events
- •Are receiving concurrent administration of anticoagulant therapy
- •Placement of Gliadel® wafer at surgery
- •Have a serious concomitant systemic disorder (for example, active infection including HIV, or cardiac disease) - participants who are pregnant, anticipate becoming pregnant within 6 months after study participation, or are currently breast-feeding
- •Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
研究组 & 干预措施
Enzastaurin Once Daily (QD)
Experimental
Enzastaurin given orally (PO) once daily (QD). 1125 mg loading dose D(-)7 then 500 mg PO,QD with concomitant radiotherapy.
干预措施: Enzastaurin 500 milligram (mg) Once Daily (QD) (Drug)
Enzastaurin Twice Daily (BID)
Experimental
Enzastaurin 1125 mg loading dose D(-)7 then 250 mg twice daily (BID) PO, with concomitant radiotherapy.
干预措施: Enzastaurin 250 mg Twice Daily (BID) (Drug)
结局指标
主要结局
Percentage of Participants With Progression Free Survival at 6 Months (PFS-6)
时间窗: Baseline to 6 months
PFS-6 is defined as the percentage of participants with PFS at 6 months from the date of diagnosis to the first date of objectively determined progressive disease (based on radiological assessment) or death from any cause. It is assumed that PFS follows an exponential distribution.Estimation using Kaplan-Meier technique.
次要结局
- Response Rate(Baseline to 30 months)
- Percentage of Participants With Overall Survival at 1 and 2 Years After Surgery(Baseline to 1 and 2 year)
- Change in Neurologic Status as Measured by Mini Mental Status Questionnaire, Total Score(Baseline through Week 12 .)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate CancerAdenocarcinoma of the ProstateRecurrent Prostate CancerStage IIB Prostate CancerStage III Prostate CancerStage IV Prostate CancerNCT02023463Thomas Jefferson University25
已完成
2 期
Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal CancerNeoplasmsCarcinomaOvarian CancerNCT00420381Eli Lilly and Company28
进行中（未招募）
1 期
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal DiseaseHER2-positive Breast CancerLeptomeningeal MetastasisLeptomeningeal DiseaseNCT04588545H. Lee Moffitt Cancer Center and Research Institute33
Unknown
2 期
Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNCT01391260ZhuGuangYing30
已完成
1 期
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent GliomasRecurrent GliomasNCT01445119Eli Lilly and Company58